Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Save on this medicine
Same active ingredient — pay up to 49% less
These brands contain the same active ingredient (Daclatasvir). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Dasvir is used together with sofosbuvir to treat long-term (chronic) hepatitis C virus (HCV) infection in adults.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Recommended Dosage: The recommended dose of Daclatasvir is 60 mg once daily, taken by mouth with or without food. Daclatasvir must always be given together with other medicines. Before starting treatment with Daclatasvir, the Summary of Product Characteristics for the other medicines in the regimen should also be consulted. The recommended regimens and treatment durations are shown in the table below. For the Daclatasvir plus Sofosbuvir regimen, data on a 12-week treatment duration are available only for treatment-naïve patients with genotype 1 infection. For Daclatasvir plus Sofosbuvir, with or without Ribavirin, data are available for patients with advanced liver disease (≥F3) without cirrhosis. The recommended use of Daclatasvir plus Sofosbuvir in genotype 4 is based on extrapolation from genotype 1. For the Daclatasvir plus Peginterferon alfa plus Ribavirin regimen, data are available for treatment-naïve patients. When Ribavirin is combined with Daclatasvir, its dose is based on body weight (1,000 mg for patients under 75 kg, or 1,200 mg for patients of 75 kg or more). Dose modification, interruption and discontinuation: Changing the dose of Daclatasvir to manage side effects is not recommended. If treatment with any component of the regimen has to be interrupted because of side effects, Daclatasvir must not be continued on its own as monotherapy. There are no virologic stopping rules for the combination of Daclatasvir with Sofosbuvir. Treatment should be discontinued in patients who show an inadequate virologic response while on Daclatasvir, Peginterferon alfa and Ribavirin. Dose recommendation for concomitant medicines: Strong inhibitors of cytochrome P450 enzyme 3A4 (CYP3A4): the dose of Daclatasvir should be reduced to 30 mg once daily when given with strong CYP3A4 inhibitors. Moderate inducers of CYP3A4: the dose of Daclatasvir should be increased to 90 mg once daily when given with moderate CYP3A4 inducers. Missed doses: Patients should be told that if they miss a dose of Daclatasvir, it should be taken as soon as possible if remembered within 20 hours of the scheduled time. If the missed dose is remembered more than 20 hours after the scheduled time, it should be skipped and the next dose taken at the usual time.
Side Effects
The following serious adverse reactions are described below and elsewhere in the labeling: serious symptomatic bradycardia when coadministered with sofosbuvir and amiodarone. A person may experience any of the following symptoms: fainting or near-fainting, dizziness or lightheadedness, not feeling well, weakness, tiredness, shortness of breath, chest pain, confusion, and memory problems.
Cautions & Contraindications
Warnings & Precautions
Drug interactions with Dasvir can cause adverse reactions or loss of virologic response. Taking Dasvir together with other drugs may lead to known or potentially significant interactions. These may result in loss of Dasvir's therapeutic effect and the possible development of resistance, a need to adjust the dose of Dasvir or the other medications, or possible clinically significant adverse reactions caused by greater exposure to Dasvir or the other drugs. Serious symptomatic bradycardia has occurred when Dasvir is coadministered with Sofosbuvir and Amiodarone, and patients should be counselled about this. Postmarketing cases of symptomatic bradycardia, including cases that required a pacemaker, have been reported when Amiodarone is coadministered with Sofosbuvir in combination with another HCV direct-acting antiviral such as Dasvir. Patients taking Sofosbuvir together with Dasvir who must start Amiodarone because no other treatment option is available should have cardiac monitoring.
Contraindications
Daclatasvir must not be used together with drugs that strongly induce CYP3A, since this may reduce exposure to Daclatasvir and cause loss of efficacy. Contraindicated drugs include, but are not limited to, anticonvulsants (phenytoin, carbamazepine), antimycobacterial agents (rifampin), and herbal products such as St. Jhon’s wort (Hypericum perforatum).